There is a pressing need for new anticoagulant therapeutics in human medicine. To meet this need, developers are reformulating traditional cornerstone therapeutics such as heparin and looking to new classes such as DTIs to prevent stroke and myocardial infarction and treat deep vein thrombosis and a host of other emerging indications.
This briefing analyzes the potential world medical markets for new anticoagulant therapies. Revenue projections through 2010 are made for four geographic regions and for two potentially blockbuster products. This report emphasizes the future markets for these products. The report generally reviews the nature and direction of research, as well as future markets. This briefing also profiles several companies involved in marketing or developing such products in the field, including AstraZeneca, Emisphere Technologies Inc., Encysive Pharmaceuticals and GlaxoSmithKline.
Market forecasts are based on an examination of current market conditions and on investigations into the development of new products by key companies. This information is also weighted with the projected timing and the probability of receiving FDA and other regulatory approval to market products. The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with company executives, clinicians, researchers and public health officials.